PRODUCT LITERATURE

Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children

---

Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

TEXTBOOK

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Molcin
Moxifloxacin
Tuberculosis in Children

Specific Detail Info

Clinical Infectious Diseases 2022;74(8):1372–81

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment